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Introduction 
 
Bladder cancer is one of the most common can-
cers in the United States, especially in men. In 
2009, there will be an estimated 70,980 new 
cases of bladder cancer with 52,810 cases in 
males [1]. Approximately 15% of bladder tumors 
evolve into invasive tumors after infiltration 
through the basement membrane. Patients with 
muscle-invasive disease are at high risk for re-
currence, progression, and metastasis. Although 
early stage bladder cancer can be treated surgi-
cally, the five-year survival is 45% and 6% for 
patients with regional and distant recurrences, 
respectively. 
 
Mice or rats administered N-butyl-N-(4-
hydroxybutyl)-nitrosamine (OH-BBN) develop 
transitional and squamous cell urinary bladder 
cancers that have significant histopathological 
similarities to human bladder cancer and are 
frequently invasive.  These rodent models have 
been used previously to characterize the tumori-
genic process for urinary bladder cancer and to 
assess the efficacy of potential chemopreven-
tive agents to inhibit the development of blad-
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Abstract:  Genes differentially expressed by tumor cells represent promising drug targets for anti-cancer therapy. 
Such candidate genes need to be validated in appropriate animal models. This study examined the suitability of ro-
dent models of bladder cancer in B6D2F1 mice and Fischer-344 rats to model clinical bladder cancer specimens in 
humans.  Using a global gene expression approach cross-species analysis showed that 13~34% of total genes in the 
genome were differentially expressed between tumor and normal tissues in each of five datasets from humans, rats, 
and mice. About 20% of these differentially expressed genes overlapped among species, corresponding to 2.6 to 
4.8% of total genes in the genome. Several genes were consistently dysregulated in bladder tumors in both humans 
and rodents. Notably, CNN1, MYL9, PDLIM3, ITIH5, MYH11, PCP4 and FMO5 were found to commonly down-
regulated; while TOP2A, CCNB2, KIF20A and RRM2 were up-regulated. These genes are likely to have conserved 
functions contributing to bladder carcinogenesis. Gene set enrichment analysis detected a number of molecular path-
ways commonly activated in both humans and rodent bladder cancer. These pathways affect the cell cycle, HIF-1 and 
MYC expression, and regulation of apoptosis. We also compared expression changes at mRNA and protein levels in 
the rat model and identified several genes/proteins exhibiting concordant changes in bladder tumors, including 
ANXA1, ANXA2, CA2, KRT14, LDHA, LGALS4, SERPINA1, KRT18 and LDHB. In general, rodent models of bladder 
cancer represent the clinical disease to an extent that will allow successful mining of target genes and permit studies 
on the molecular mechanisms of bladder carcinogenesis.  
 
Keywords: Human bladder cancer, rodent models, gene expression, proteomics, and cross-species comparison. 
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der cancers [2-6]. However, to what degree car-
cinogen-induced rodent models recapitulate 
molecular features and biological pathways of 
human bladder cancer has not been character-
ized.  
 
Many biological systems operate in an evolu-
tionarily conserved manner across a large num-
ber of species. Cross-species analysis of se-
quence and gene interaction is often applied to 
determine the function of new genes. In con-
trast to these static measurements, microarrays 
measure the dynamic, condition-specific re-
sponse of complex biological systems. The re-
cent exponential growth in microarray expres-
sion datasets allows researchers to combine 
expression experiments from multiple species 
to identify genes that are not only conserved in 
sequence but also regulated in a similar way 
across species. In this study we performed 
cross-species analysis of microarray data for 
human bladder cancer and carcinogen induced 
rodent bladder cancer. The major objectives of 
this study were to identify the degree of cross-
species overlap on the single-gene level and to 
determine the similarity of the biological path-
ways in the cross-species comparison that may 
be relevant to the mechanism of bladder car-
cinogenesis. Our analysis demonstrates that 
cross-species comparisons can be used to ob-
tain important information on gene expression 
and pathway activation that cannot be obtained 
when analyzing data from a single species.  
 
Materials and Methods 
 
Rodent models of bladder cancer  
 
Female Fischer-344 rats and male B6D2F1 
(C57Bl/6 x DBA/2 F1) mice were obtained from 
Harlan Sprague-Dawley, Inc. (Indianapolis, IN; 
virus-free colony 202) at 28 days of age and 
were housed in polycarbonate cages (five per 
cage). The animals were kept in a lighted room 
12 hours each day and maintained at 22 ± 0.5°
C. Teklad 4% mash diet (Harlan Teklad, Madi-
son, WI) and tap water were provided ad libi-
tum. In the mouse study, at 56 days of age, ani-
mals received the first of 12 weekly gavage 
treatments with OH-BBN (TCI America, Portland, 
OR). Each 7.5-mg dose was dissolved in 0.1 ml 
ethanol: water (25:75). For the rat study, OH-
BBN (150 mg/gavage, 2x/week) was started 
when the rats were 49 days of age and contin-
ued for 8 weeks. The carcinogen vehicle was 
ethanol:water (20:80) in 0.5 ml. All animals 
were sacrificed 8 months following the initial OH
-BBN treatment.  
 
Bladder tumors were removed and frozen for 
subsequent molecular assays. All frozen tumor 
tissues were microdissected to determine the 
tumor vs normal cell ratio for each specimen. 
Only microscopic sections from tumor tissues 
containing more than 80% tumor cells were 
isolated and stored at -80°C for subsequent 
RNA isolation. A portion of each tumor was fixed 
and processed for routine paraffin embedding, 
cut into 5-µm sections, and mounted for hema-
toxylin and eosin (H&E) staining. All bladder tu-
mors used in this study were diagnosed as blad-
der cancers with a mixed histology showing ele-
ments of both transitional and squamous cells. 
Matching normal epithelia came from the same 
sex and age-matched controls were also micro-
dissected to ensure that specimens consisted 
of purely normal lung tissue. To isolate bladder 
epithelia, we separated epithelial cells from the 
stroma and muscle tissues by cutting the blad-
der into half and scraping off the epithelium.  
 
Total RNA from normal bladder epithelia and 
bladder tumors were isolated by Trizol 
(Invitrogen, Carlsbad, CA) and purified using the 
RNeasy Mini Kit and RNase-free DNase Set 
(QIAGEN, Valencia, CA) according to the manu-
facturer's protocols. In vitro transcription-based 
RNA amplification was then performed on each 
sample. cDNA for each sample was synthesized 
using a Superscript cDNA Synthesis Kit 
(Invitrogen) and a T7-(dT)24 primer, 5′-
G G C C A G T G A A T T G T A A T A C G A C T C A C T A -
TAGGGAGGCGG-(dT)24-3′. cDNA were cleaned 
using phase-lock gels (Fisher cat ID 
E0032005101) and phenol/chloroform extrac-
tion. Then, biotin-labeled cRNA were transcribed 
in vitro from cDNA using a BioArray High Yield 
RNA Transcript Labeling Kit (ENZO Biochem, 
New York, NY) and purified again using the 
RNeasy Mini Kit. The labeled mouse cRNA were 
applied to Affymetrix MGU74Av2 GeneChips and 
the labeled rat cRNA were applied to Affymetrix 
Rat230 2.0 GeneChips or Rat Exon 1.0 ST Array 
(Affymetrix) according to the manufacturer's 
recommendations. The raw fluorescence inten-
sity data within CEL files from the platform Affy-
metrix MGU74Av2 and Rat230 2.0 were pre-
processed with Robust Multichip Average (RMA) 
algorithm [7], as implemented with R packages 
A f f y  f r o m  B i o c o n d u c t o r  ( h t t p : / /
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www.bioconductor.org). This algorithm analyzes 
the microarray data in three steps: a back-
ground adjustment, quantile normalization, and 
finally summation of the probe intensities for 
each probe set using a log scale linear additive 
model for the log transform of (background cor-
rected, normalized) PM intensities. Gene-level 
signal estimates for the CEL files from the plat-
form Rat Exon 1.0 ST Array were derived by 
quantile sketch normalization using Iterplier 
algorithm, as implemented with Expression Con-
sole v1.1.1 (http://www.affymetrix.com/
p r o d u c t s_ se r v i c e s / s o f t w ar e / s p e c i f i c /
expression_console_software.affx). 
 
For 1D protein gel electrophoresis, rat samples 
were solubilized in the following lysis buffers: 25 
mM Hepes buffer containing 150 mM NaCl, 10 
mM MgCl2, 1% Igepal, 0.25% sodium deoxycho-
late, 10% glycerol, 2.5 mM EDTA, and protease/
phosphatase inhibitors. For 2D protein differ-
ence electrophoresis, rat samples were solubi-
lized in 100 μL of lysis buffer (30 mM Tris-Cl, pH 
8.5; 7 M urea, 2 M thiourea, 4% CHAPS) con-
taining protease inhibitor cocktail (Roche, Indi-
anapolis, IN) and phosphatase inhibitor cock-
tails I and II) (Sigma-Aldrich, St. Louis, MO). After 
centrifugation at 15,000 rpm for 30 min, the 
supernatant was recovered as cellular protein 
for the protein expression study. Protein sam-
ples from carcinogen-treated and control rats 
were labeled with DIGE fluorescent dye (GE 
Healthcare Amersham Biosciences, Piscataway, 
NJ), and analysis was performed as described 
previously [8]. A pooled sample consisting of a 
mixture of small portions of all protein samples 
obtained was used as internal control. Briefly, 
after extraction in lysis buffer, three cyanine 
dyes, Cy2, Cy3, and Cy5 were used to label the 
protein samples from normal rats, pooled sam-
ple, and carcinogen-treated rats, respectively. 
The same amount of protein were combined 
and analyzed on the same gel. For the first-
dimension separation, the labeling mixture was 
applied to Immobiline DryStrips (24 cm long, pH 
3 to 10; GE Healthcare). The second dimension 
was carried out with 10-20% SDS-PAGE gels. 
The Cy2, Cy3, and Cy5-labeled images were 
subsequently acquired at the recommended 
wavelengths using a Typhoon 9400 scanner (GE 
Healthcare). Comprehensive image analysis was 
performed using DeCyder-2D Differential Analy-
sis Software 5.0 (GE Healthcare). For spot de-
tection and quantification, the differential in-gel 
analysis (DIA) module of DeCyder was em-
ployed. The biological variance analysis module 
(BVA) was then used to match the quantified 
spots of all gels to a chosen master gel. The 
statistical significance of each expression level 
was calculated using the Student’s t-test in the 
BVA module. Protein expression levels which 
showed a statistically significant (p<0.05) in-
crease or decrease were defined as being sig-
nificant.  In addition to log standardized abun-
dances, the matched spot raw volume data of 
each sample was used in this analysis. A ratio 
was created by comparing the raw volume of 
each protein spot to that of its intra-gel internal 
standard. Selected gel features were excised 
and digested in situ with trypsin as described 
previously [8]. The resulting peptide pools were 
analyzed by tandem mass spectrometry using 
both MALDI-TOF/TOF instrument (Proteomics 
4700, Applied Biosystems, Framingham, MA) 
and LC-MS/MS (LTQ-FTMS, Thermolelectron, 
San Jose, CA) performed as described [9]. The 
peptide fragmentation spectra were processed 
using Data Explorer, v 4.5 and Analyst software 
(Applied BioSystems, Framingham, MA and To-
ronto, Ontario). The processed spectra were 
used to search protein and conceptually-
translated database with MASCOT, v 1.9 (Matrix 
Sciences, London, UK). Precursor error toler-
ance was set to 100 ppm and MS/MS fragment 
error tolerance, 0.8 Da. All the proteins identi-
fied should have protein scores greater than 40 
and individual ions scores greater than 20 with 
expected value < 0.05. All the MS/MS spectra 
were further validated manually. When multiple 
proteins were identified in a single spot, the 
proteins with the highest number of peptides 
were considered as those corresponding to the 
spot. 
 
Human bladder cancer  
 
The expression data for human clinical speci-
mens from two published study were used. Both 
of these two studies performed gene expression 
profiles on the Human Genome U133A human 
GeneChips containing 22,283 probes repre-
senting known genes and expression sequence 
tags (Affymetrix). One dataset is the study of 
Dyrskjøt et al. [10] including biopsies of normal 
bladder mucosa from 9 patients without a blad-
der cancer history, histologically normal mucosa 
biopsies from 5 cystectomy specimens, biopsies 
from 28 superficial transitional cell bladder tu-
mors (13 tumors with surrounding carcinoma in 
situ  and 15 without surrounding carcinoma in 
Cross-species gene-expression of bladder cancer  
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situ) and 13 invasive transitional cell carcino-
mas. The CEL files were downloaded from Gene 
Expression Omnibus (GEO accession number: 
GSE3167).  The raw fluorescence intensity data 
within CEL files were preprocessed with RMA 
algorithm.  Another dataset is the study of San-
chez-Carbayo et al. [11], including 49 normal 
urothelium specimens which were obtained at 
distant sites from the bladder tumors resected 
by cystectomy or cystoprostatectomy and 109 
bladder cancer (28 superficial and 81 invasive 
lesions). The expression data of the 157 blad-
der tissues under study derived by the Affy-
metrix Microarray Suite 5.0 (MAS 5.0) were in-
cluded in Supplemental table 10 of the original 
paper (http://jco.ascopubs.org/cgi/content/
full/JCO.2005.03.2375/DC1). Basic informa-
tion of these five microarray datasets used for 
cross-species gene-expression analysis of blad-
der cancer is found in Table 1.  
 
Statistical analyses 
 
The probe sets with the average gene expres-
sion level of both tumor and normal groups less 
than 64 derived by MAS 5.0 and Iterplier or less 
than 6 derived by RMA were excluded in the 
following statistical analyses.  Two-sample stu-
dent t test was used to identify differentially 
expressed genes (DEGs) between tumor and 
normal groups for each dataset. To adjust the 
multiple testing in the study of high-dimensional 
microarray data, both tail area-based false dis-
covery rate values (Q values) and local false 
discovery rate (LFDR) were estimated [12], 
which was implemented in R package fdrtool 
(http://www.r-project.org/). The DEGs were de-
fined as genes with Q value < 0.01, LFDR < 
0.05 and fold change > 1.5 between two 
groups.  
Gene set enrichment analysis (GSEA) was per-
formed to analyze the pattern of differential 
gene expression in each dataset respectively. 
GSEA is a computational method that deter-
mines whether a set of genes shows statistically 
significant differences in expression between 
two biological states, which has proved success-
ful in discovering molecular pathways involved 
in human diseases (http://www.broad.mit.edu/
gsea). Using the Kolmogorov-Smirnov statistic, 
GSEA assesses the degree of “enrichment” of a 
set of genes (e.g. a pathway) in the entire range 
of the strength of associations with the pheno-
type of interest. It was used to identify a priori 
defined sets of genes that were differentially 
expressed [13, 14]. We used curated gene sets 
(c2) which contain genes on certain molecular 
pathways, and GO gene sets (c5) which consist 
of genes annotated by the same GO terms in 
the Molecular Signature Database (MSigDB, 
http://www.broad.mit.edu/gsea/msigdb/
msigdb_index.html). For datasets of rodent 
models, because of small sample size, GSEA 
with gene permutation option was performed. 
Selected gene sets identified from GSEA were 
then visualized with MetaCore™ (http://
www.genego.com/).  
Quantitative Real-time PCR 
 
Using the samples from rat model of bladder 
cancer, the relative expressions of eight random 
selected genes associated with survival were 
determined by QRT-PCR. RNA was isolated using 
Trizol reagent per manufacturer’s instructions 
(Invitrogen). One micrograms of total RNA per 
sample were converted to cDNA using the Im 
Prom-II RT kit (Promega Co. Madison, WI) for RT-
PCR (Invitrogen). Primers for QRT-PCR analysis 
(Table 2) were designed using Primer Express 
software version 2.0 (Applied Biosystems, Fos-
ter City, CA). Amplification of each target DNA 
was performed with SYBR Green PCR Supermix
Table 1. Datasets in cross-species gene-expression analysis of bladder cancer  
 
Datasets No. of normal No. of tumor GEO PubMed 
Human_1 14 41 GSE3167 15173019 
Human_2 49 109 N/A 16432078 
Rat_1 5 5 N/A 17401461 
Rat_2* 7 11 N/A N/A 
Mouse 4 4 N/A 15548366 
*These are new microarray data from Rat Exon 1.0 ST arrays used for the present study. 
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(BIO-RAD, Hercules, CA) in BIO-RAD Single Color 
Real-Time PCR Detection system according to 
the protocols provided. One microliter of cDNA 
was added to a 25 mL total volume reaction 
mixture containing water, SYBR Green PCR Su-
perMix, and primers. Each real-time assay was 
done in triplicate on a BioRad MyIQ thermal 
cycler. Data were collected and analyzed with 
iQ5 optical system software, version 2.1 soft-
ware. The internal control gene GAPDH and tar-
get genes were amplified with equal efficien-
cies. The method for assessing if two amplicons 
have the same efficiency is to look at how ΔCT 
(CT,target – CT,GAPDH, CT is cycle number at which 
the fluorescence signal exceeds background) 
varies with template dilution. Smaller ΔCT indi-
cates higher gene expression. The fold change 
of gene expression in the tumor tissues relative 
to the normal tissues was calculated as 2-ΔΔCT 
(ΔΔCT = ΔCT tumor – ΔCT normal). The differences in 
expression between two groups were deter-
mined by two-tailed Student’s t-test. A P-value of 
less than 0.05 was considered to indicate sta-
tistical significance.  
Results 
 
Differentially expressed bladder cancer genes 
in each species 
 
Five microarray datasets were used for cross-
species gene-expression analysis of bladder 
cancer including two human datasets, two rat 
datasets and one mouse dataset (Table 1). One 
of two rat datasets is our new microarray data 
from Rat Exon 1.0 ST arrays. We applied a cut-
off of Q value < 0.01, LFDR < 0.05 and fold 
change > 1.5 to detect genes differentially regu-
lated between tumors and normal bladder tis-
sues in all datasets. Table 3 listed total num-
bers and proportion of genes differentially regu-
lated between tumor and normal bladder tis-
sues in each dataset. We first randomly chose 
eight DEGs and evaluated the microarray gene 
expression results from the cross-species analy-
sis. The relative expression of these candidate 
bladder cancer genes was determined by QRT-
PCR analysis using the samples from the rat 
model. We confirmed the expression results for 
Table 2. Oligonucleotide primers and probes used for quantitative real-time PCR Analysis  
 
Gene Sense primer Anti-sense primer 
GAPDH GACATGCCGCCTGGAGAA CTCGGCCGCCTGCTT 
ANXA2 GACATTGCCTTCGCCTACCA ACCAGACAAGGCCGACTTCA 
TUBB5 TCCGTTCGCTCAGGTCCTT CTGCCCCAGACTGACCAAAA 
NDN GGACAGAGTCGCGCTGAAC TCACATAGATGAGACTCAGGATCATGA 
KIF2c GGAAGGTATTTGATCTGCTCAACAA CAACCTGCACCTGCTGCTT 
KIF22 CCCAGAAATTAAGCCTCTTACAGAA CCCAGCAAACGTTCCATACTC 
CCNA2 ACAGTATGCGGGCCATCCT AGCCAAATGCAGGGTCTCAT 
INHBA GGCAGGAGGGCCGAAAT CCTGACTCGGCAAAGGTGAT 
E2F8 ACTTTCCCCAAACCACAGGAT CGACGCCACTGGGATCA 
Table 3. Total number and proportion of genes differentially regulated between tumor and normal bladder 
tissues*  
 
  Up-regulated in tumor   Down-regulated in tumor 
Number Proportion (%) Number Proportion (%) 
Human_1 2729 14.7   2233 12.0 
Human_2 3104 24.5   1352 10.7 
Rat_1 816 6.5   789 6.3 
Rat_2 1069 6.8   1137 7.2 
Mouse 514 6.5   621 7.8 
*The DEGs were defined as genes with Q value < 0.01, LFDR < 0.05 and fold change > 1.5 between two groups. 
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all of the eight selected genes (CCNA2, TUBB5, 
KIF22, INHBA, E2F8, ANXA2, KIF2C and NDN) 
(p≤ 0.05) (Figure 1). This warrant further investi-
gation and comparison of DEGs among different 
species.   
 
Approximately, 26 to 34% of genes were identi-
fied as DEGs in the two human datasets while 
only 13 to 14% were in the rodent models. 
About 14% of DEGs were identified in both hu-
man datasets, including 891 up-regulated 
genes and 328 down-regulated genes. 7.9% of 
DEGs were identified in both rat datasets, in-
cluding 181 up-regulated genes and 232 down-
regulated genes. About 20% of these DEGs 
overlapped among species, corresponding to 
2.6 to 4.8% of total genes in the genome (Table 
4).  This suggests that although a large number 
of genes were identified to be differentially ex-
pressed between bladder tumor and normal 
tissues in each species, most of these genes 
are not common to the models. These genes 
Figure 1. QRT-PCR validation of several candidate bladder cancer genes. Columns represent fold changes for the 
selected genes with differential expression between normal and tumor samples.. *: P≤0.05; **: P≤0.01; ***: 
P≤0.005 
Table 4. Cross-species overlap of single differentially expressed genes as absolute number or proportion 
(in brackets) of overlapping orthologous genes between data sets* 
 
  Human_1 Human_2 Rat_1 Rat_2 Mouse 
Human_1   891 (10.4%) 165 (2.9%) 177 (2.9%) 154 (3.1%) 
Human_2 328 (3.8%)   112 (2.2%) 103 (2.1%) 131 (3.0%) 
Rat_1 72 (1.3%) 21 (0.4%)   181 (3.5%) 96 (2.4%) 
Rat_2 115 (1.9%) 56 (1.2%) 232 (4.4%)   86 (2.2%) 
Mouse 112 (2.2%) 44 (1.0%) 69 (1.7%)  82 (2.1%)   
*Up triangle, up-regulated genes in tumors; down triangle , down-regulated gene in tumors. 
Cross-species gene-expression of bladder cancer  
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may result from the cancer rather than being 
causally related.  
 
The top 100 DEGs in each dataset were com-
pared. 91 genes were consistently dysregulated 
in at least two datasets, including 54 down-
regulated genes and 37 up-regulated genes 
(Table 5 and 6). Several genes were consis-
tently dysregulated in bladder tumors in both 
humans and rodents. These genes are likely to 
have conserved functions contributing to blad-
der carcinogenesis. These include, CNN1 
(calponin 1, basic, smooth muscle), MYL9 
(myosin, light chain 9, regulatory), PDLIM3 (PDZ 
and LIM domain 3), ITIH5 (inter-alpha (globulin) 
inhibitor H5), MYH11 (myosin, heavy chain 11, 
smooth muscle), PCP4 (Purkinje cell protein 4) 
and FMO5 (flavin containing monooxygenase 5) 
which were found to be commonly down-
regulated; while TOP2A (topoisomerase (DNA) II 
alpha 170kDa), CCNB2 (cyclin B2), KIF20A 
(kinesin family member 20A) and RRM2 
(ribonucleotide reductase M2 polypeptide) were 
found to be commonly up-regulated.  
 
Proteomic analysis 
 
We then evaluated the concordance between 
gene expression and protein abundance in ro-
dent models of bladder cancer. Ninety-six pro-
teins that were significantly changed between 
normal and tumor in rat bladder samples were 
identified using a process of two-dimensional 
differential gel electrophoresis (2D-DIGE), in situ 
gel digestion, tandem mass spectrometry, and 
database searching (Table 7). Compared with 
the results from the transcriptomic analyses, 21 
genes exhibited concordant changes at the 
mRNA and protein level in at least one rat 
mRNA expression dataset (Table 8). Among 
them, ANXA1 (annexin A1), ANXA2 (annexin A2), 
CA2 (carbonic anhydrase II), KRT14 (keratin 
complex 1, acidic, gene 14), LDHA (lactate de-
hydrogenase A), LGALS4 (lectin, galactoside-
binding, soluble, 4) and SERPINA1 (serine (or 
cysteine) proteinase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1) were 
increased in both rat gene expression datasets 
and concordant changes were observed at the 
protein level. KRT18 and LDHB were decreased 
in both rat datasets and showed concordant 
changes at the protein level (Table 9). The re-
mainder did not show significant differences in 
gene expression, or showed discordant 
changes. These results suggest that many pro-
teins which are changed in tumor might involve 
post-translational modification and the expres-
sion changes cannot be observed at the tran-
scriptional level.  
 
Molecular pathways identified by gene enrich-
ment analysis (GSEA) 
 
GSEA was performed using the curated gene 
sets to identify molecular pathways involved in 
bladder carcinogenesis. A false discovery rate 
(FDR) of ≤ 0.25 was used for defining GSEA en-
riched gene sets [13, 14]. Using the curated 
gene sets c2, GSEA detected 74 enriched gene 
sets in bladder tumors in all of the five datasets 
from three different species (Table 10). These 
pathways include cell cycle, HIF-1 (hypoxia-
inducible factor 1) and MYC pathways which 
were activated in bladder tumors. GSEA also 
detected additional 14 enriched gene sets 
among all of the five datasets using the curated 
gene sets c5 (Table 10). Several pathways are 
particularly interesting, including apoptosis, and 
the mitotic (M) phase of the cell cycle (Figure 2 
and 3). Dysregulated genes are significantly 
over-represented in these pathways during blad-
der neoplastic transformation and progression 
in both humans and rodents.  
 
Discussion 
 
Rodent models represent a powerful tool in the 
research of cancer mechanisms, prevention and 
therapy. Determination of the extent as to which 
findings in animal models can be translated to 
human disease is an important step. In this 
study we examined whether global gene expres-
sion profiling can assist in determining the suit-
ability of rodent models of bladder cancer for 
the detection of cancer-related genes and pre-
diction of cancer prevention effects.  
 
The present study found that rodent models of 
bladder cancer (in OH-BBN treated B6D2F1 
mice and Fischer-344 rats) accurately represent 
the clinical situation to an extent that will allow 
successful mining of target genes. About 20% of 
DEGs in bladder tumors overlapped among spe-
cies, corresponding to 2.6 to 4.8% of total 
genes in the genome. Several genes that were 
concordantly regulated across species are of 
particular interest. Among these genes is ribo-
nucleotide reductase M2 polypeptide (RRM2) 
which was increased in tumors across three 
species. RRM2 is an enzyme that catalyzes the 
Cross-species gene-expression of bladder cancer  
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Table 5. Down-regulated genes observed in at least two datasets* 
 Genes Description Datasets 
CASQ2 calsequestrin 2 (cardiac muscle) human1, human2 
DES desmin human1, human2 
DMD dystrophin (muscular dystrophy, Duchenne and Becker types) human1, human2 
DMN desmuslin human1, human2 
FHL1 four and a half LIM domains 1 human1, human2 
FOXF1 forkhead box F1 human1, human2 
KIAA0367 KIAA0367 human1, human2 
LMOD1 leiomodin 1 (smooth muscle) human1, human2 
PLN phospholamban human1, human2 
PTGIS prostaglandin I2 (prostacyclin) synthase human1, human2 
REEP1 receptor accessory protein 1 human1, human2 
SORBS1 sorbin and SH3 domain containing 1 human1, human2 
TNS1 tensin 1 human1, human2 
TPM2 tropomyosin 2 (beta) human1, human2 
CNN1 calponin 1, basic, smooth muscle human1, human2, mouse 
MYL9 myosin, light chain 9, regulatory human1, human2, mouse 
PDLIM3 PDZ and LIM domain 3 human1, human2, mouse 
ITIH5 inter-alpha (globulin) inhibitor H5 human1, mouse 
MYH11 myosin, heavy chain 11, smooth muscle human2, mouse 
PCP4 Purkinje cell protein 4 human2, mouse 
FMO5 flavin containing monooxygenase 5 rat1, mouse 
ACE2 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 rat1, rat2 
AHRR aryl-hydrocarbon receptor repressor rat1, rat2 
CAPN13 calpain 13 rat1, rat2 
CASKIN1 CASK interacting protein 1 rat1, rat2 
CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 rat1, rat2 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 rat1, rat2 
CYP3A18 cytochrome P450, family 3, subfamily A, polypeptide 18 rat1, rat2 
DPYD dihydropyrimidine dehydrogenase rat1, rat2 
EGFL6 EGF-like-domain, multiple 6 rat1, rat2 
FNDC5 fibronectin type III domain containing 5 rat1, rat2 
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 rat1, rat2 
HTR4 5-hydroxytryptamine (serotonin) receptor 4 rat1, rat2 
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 rat1, rat2 
PAK3 p21 (CDKN1A)-activated kinase 3 rat1, rat2 
PCBP3 poly(rC) binding protein 3 rat1, rat2 
PLAG1 pleiomorphic adenoma gene 1 rat1, rat2 
PLCE1 phospholipase C, epsilon 1 rat1, rat2 
PRKCQ protein kinase C, theta rat1, rat2 
RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 rat1, rat2 
SHANK2 SH3 and multiple ankyrin repeat domains 2 rat1, rat2 
SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 rat1, rat2 
SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 rat1, rat2 
TRPV4 transient receptor potential cation channel, subfamily V, member 4 rat1, rat2 
TSHR thyroid stimulating hormone receptor rat1, rat2 
KRT20 keratin 20 rat1, rat2, mouse 
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 rat1, rat2, mouse 
SH3GL2 SH3-domain GRB2-like 2 rat1, rat2, mouse 
SLC16A7 solute carrier family 16, member 7 (monocarboxylic acid transporter 2) rat1, rat2, mouse 
FLJ45455 
(RGD1564618) FLJ45455 protein (similar to novel protein) rat2, human2 
HIP1R huntingtin interacting protein 1 related rat2, mouse 
NDRG2 NDRG family member 2 rat2, mouse 
UPK2 uroplakin 2 rat2, mouse 
MFSD4 major facilitator superfamily domain containing 4 rat2, mouse 
* The DEGs were defined as genes with Q value < 0.01, LFDR < 0.05 and fold change > 1.5 between two groups;  the top 100 DEGs in each 
dataset were compared. 
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formation of deoxyribonucleotides from ribonu-
cleotides [15]. Deoxyribonucleotides in turn are 
used in the synthesis of DNA. The reaction cata-
lyzed by RRM2 is strictly conserved in all living 
organisms [16]. Furthermore RRM2 plays a criti-
cal role in regulating the total rate of DNA syn-
thesis so that DNA to cell mass is maintained at 
a constant ratio during cell division and DNA 
repair [17]. RRM2 plays an important role in 
tumor angiogenesis and growth through regula-
tion of the expression of TSP-1 and VEGF [18]. 
TOP2A was consistently increased across data-
sets and encodes a DNA topoisomerase, an 
enzyme that controls and alters the topologic 
states of DNA during transcription. TOP2A plays 
an important role in checkpoint activation and 
the maintenance of genomic stability [19].   
Increased TOP2A correlated with advanced his-
tological grading, microvascular invasion, and 
an early age onset of the hepatocellular        
Table 6. Up-regulated genes observed in at least two datasets* 
 
Genes Description Datasets 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) human1, human2 
EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1 human1, human2 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) human1, human2 
KRT7 keratin 7 human1, human2 
LSR lipolysis stimulated lipoprotein receptor human1, human2 
MLF1IP MLF1 interacting protein human1, human2 
PRC1 protein regulator of cytokinesis 1 human1, human2 
SLC38A1 solute carrier family 38, member 1 human1, human2 
SPINT1 serine peptidase inhibitor, Kunitz type 1 human1, human2 
TH1L TH1-like (Drosophila) human1, human2 
TOP2A topoisomerase (DNA) II alpha 170kDa human1, human2, mouse 
CCNB2 cyclin B2 rat1, human1 
KIF20A kinesin family member 20A rat1, human1 
RRM2 ribonucleotide reductase M2 polypeptide rat1, human1, mouse 
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) rat1, mouse 
CTGF connective tissue growth factor rat1, mouse 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) rat1, mouse 
S100A9 S100 calcium binding protein A9 rat1, mouse 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 rat1, mouse 
DDIT4 DNA-damage-inducible transcript 4 rat1, rat2 
KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 rat1, rat2 
MALL mal, T-cell differentiation protein-like rat1, rat2 
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) rat1, rat2 
PROM1 prominin 1 rat1, rat2 
RGD1563692  rat1, rat2 
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A rat1, rat2 
TRPV2 transient receptor potential cation channel, subfamily V, mem-ber 2 rat1, rat2 
TSPAN1 tetraspanin 1 rat1, rat2 
VWA1 von Willebrand factor A domain containing 1 rat1, rat2 
VWF von Willebrand factor rat1, rat2 
WIF1 WNT inhibitory factor 1 rat1, rat2 
FGFBP1 fibroblast growth factor binding protein 1 rat1, rat2, mouse 
GPX2 glutathione peroxidase 2 (gastrointestinal) rat1, rat2, mouse 
MMP12 matrix metallopeptidase 12 (macrophage elastase) rat1, rat2, mouse 
ANXA8 annexin A8 rat2, mouse 
BHLHB2 basic helix-loop-helix domain containing, class B, 2 rat2, mouse 
MMP13 matrix metallopeptidase 13 (collagenase 3) rat2, mouse 
* The DEGs were defined as genes with Q value < 0.01, LFDR < 0.05 and fold change > 1.5 between two groups;  the top 100 
DEGs in each dataset were compared. 
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Table 7.  Protein changed signficantly between rat tumors and normal bladder tissues 
Gene Symbol Protein Name Gene Bank gi Fold
AK2 adenylate kinase 2 13591872 -2.5
AK3 adenylate kinase 3 6978479 3.2 
AKR1A1 aldo-keto reductase family 1, member A1 13591894 6.2 
ALB Albumin 55391508 4.6 
ALDH2 mitochondrial aldehyde dehydrogenase precursor 45737868 -5.8 
ALDH3A1 aldehyde dehyrogenase family 3, member A1 47482124 4.6 
ALDH3B1 fatty aldehyde dehydrogenase-like 55742838 -3.8 
ANXA1 Lipocortin I [Rattus sp.] 235879 3.4 
ANXA2 Calpactin I heavy chain 312253 7.1 
APOA4 Apolipoprotein A-IV 60552712 -3.5 
BANF1 barrier to autointegration factor 1 16758438 4.9 
CA2 Ca2 protein (carbonic anhydrase) 41388872 3.4 
CA3 carbonic anhydrase 3 31377484 -5.5 
CACYBP calcyclin binding protein 51948388 -2.5 
CCT2 chaperonin containing TCP1, subunit 2 (beta) 54400730 4.0 
CCT4 chaperonin delta subunit 33149357 8.5 
CKB creatine kinase 203474 4.9 
CNN1 calponin 313818 3.0 
DCTN2 dynactin 2 51948450 -4.3 
DES desmin 38197676 -2.2 
DYNC1LI2 lumican 13591983 4.2 
ENTPD5 ectonucleoside triphosphate dephosphorylase 40786479 -13.1 
FAM65B Liver-regeneration-related protein LRRG069 (Ab2-162) 33086566 -9.5 
GC vitamin D binding protein prepeptide 203927 3.8 
GDA guanine deaminase 7533042 3.8 
GSTA4 similar to GST 8 (8-8) 27720723 4.2 
GSTA5 glutathione-S-transferase, alpha type2 51036637 9.9 
GSTM5 glutathione transferase (EC 2.5.1.18) 204501 4.0 
GSTP1 GST pi2 25453412 5.4 
HIBCH 3-hydroxyisobutyryl-Coenzyme A hydrolase (predicted) 61556993 6.2 
HSPB1 heat shock protein 27 204665 3.4 
KA11 type I keratin KA11 57012432 4.2 
KRT10 keratin 10 57012436 1.3 
KRT13 keratin 13 51591909 4.3 
KRT14 keratin complex 1, acidic, gene 14 (predicted) 56912233 4.4 
KRT15 type I keratin KA15 51591903 -1.8 
KRT16 type I keratin KA16 56847618 -2.0 
KRT18 keratin complex 1, acidic, gene 18 60688216 -18.9 
KRT19 keratin complex 1, acidic, gene 19 42409519 -12.6 
KRT20 keratin 20 27465585 5.9 
KRT4 type II keratin Kb4 57012360 7.6 
KRT5 type II keratin 5 [Mus musculus] 16303309 5.7 
KRT7 similar to keratin complex 2 (predicted) 34868200 -5.1 
KRT73 type II keratin Kb36 57012358 -5.0 
KRT8 cytokeratin-8 [Rattus sp.] 30352203 -10.6 
LDHA lactate dehydrogenase A 8393706 3.3 
LDHB lactate dehydrogenase B 6981146 -3.5 
LGALS4 lectin, galactoside-binding, soluble, 4 (galectin 4) 6981152 4.3 
LZIC leucine zipper and CTNNBIP1 domain containing 61557405 9.8 
MDH2 malate dehydrogenase, mitochondrial 42476181 4.0 
MYL9 myosin regulatory light chain, isoform C [Rattus sp.] 998522 5.0 
NAGA N-acetyl galactosaminidase, alpha (predicted) 58865810 5.9 
NIT1 Nit 1 protein 56268926 -2.4 
NME2 RBL-NDP kinase 18kDa subunit (p18) 206580 8.0 
NQO2 NAD(P)H dehydrogenase, quinone 2 51948400 2.4 
PA2G4 proliferation associated 2G4, 38kDa 51948384 6.0 
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PDIA6 CaBP1 488838 -7.7 
PDLIM1 LIM protein 8393153 3.9 
PECR peroxisomal trans-2-enoyl-CoA reductase 18959236 4.3 
PGRMC1 progesterone receptor membrane component 1 11120720 3.7 
PKLR L-type pyruvate kinase 297533 4.2 
PKM2 Unnamed protein product 56929 4.2 
PPM1F protein phosphatase 1F (PP2C domain containing) 28461153 5.9 
PPP1R7 Protein phosphatase 1, regulatory (inhibitor) subunit 7 57032943 -34.9 
PRDX2 peroxiredoxin 2 8394432 8.0 
PRELP proline arginine-rich end leucine-rich repeat protein 16758116 8.5 
PRKCDBP protein kinase C, delta binding protein 19745164 -3.5 
PROSC similar to Proline synthetase associated(predicted) 62662820 -6.1 
PSMC4 proteasome 26S ATPase subunit 4 25742677 -3.9 
PTGR1 Leukotriene B4 12-hydroxydehydrogenase 59809128 8.1 
PZP alpha-1-macroglobulin 202857 -3.5 
RPSA laminin receptor 1 8393693 -4.3 
RUVBL1 RuvB-like protein 1 22208848 4.0 
RUVBL2 RuvB-like 2 70794778 -15.7 
S100A4 S100 A4 (calvasculin) 6981326 5.3 
S100A6 S100 calcium binding protein A6 (calcyclin) 16758986 4.9 
SAE1 Ubiquitin-like 1 (sentrin) activating enzyme E1A 50925905 -3.5 
SELENBP1 selenium binding protein 2 18266692 4.0 
SERPINA1 serine protease inhibitor alpha 1 51036655 2.5 
SERPINH1 serpinh 1 protein 55824765 4.6 
SNCG synuclein, gamma [Mus musculus] 6755592 -3.2 
STRAP serine/threonine kinase receptor associated protein 4063383 -18.5 
TALDO1 transaldolase 12002054 4.1 
TCAG7.1260 aldoketoreductase family 1 27465603 8.8 
TGM2 transglutaminase 2, C polypeptide  42476287 5.1 
TKT transketolase 1729977 6.0 
TPM1 tropomyosin alpha isoform 14134104 4.0 
TUBA1C tubulin, alpha 6 (predicted) 58865558 -2.8 
TXN thioredoxin 16758644 10.4 
UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2 24817674 4.3 
UCHL1 ubiquitin carboxy-terminal hydrolase L1 61098212 3.4 
VDAC1 voltage dependent anion channel 4105605 6.5 
VIM vimentin 57480 4.1 
YARS Yars predicted protein 68534287 6.0 
YWHAE Tyrosine 3-monooxygenase 30583161 -3.8 
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Table 8.  Genes exhibited concordant changes at both gene expression and protein levels 
  
Symbol 
 mRNA expression arrays*      Protein expression arrays† 
Gene Name probe_set Fold Q-value LFDR Dataset   Protein Name Gene Bank gi Fold 
Anxa1 annexin A1 1367614_at 12.3 3.2E-05 3.6E-05 Rat1 Lipocortin I [Rattus sp.] 235879 3.4 
Anxa2 annexin A2 1367584_at 2.7 5.2E-04 7.9E-04 Rat1 Calpactin I heavy chain 312253 7.1 
Car2 carbonic anhydrase II 1367733_at 3.4 1.4E-03 2.7E-03 Rat1 Ca2 protein (carbonic anhydrase) 41388872 3.4 
Car2 carbonic anhydrase II 1386922_at 3.1 2.5E-03 6.4E-03 Rat1 Ca2 protein (carbonic anhydrase) 41388872 3.4 
Gda guanine deaminase 1387659_at 3.1 2.0E-03 4.3E-03 Rat1 guanine deaminase 7533042 3.8 
Krt14 keratin 14 1371895_at 22.5 3.0E-05 3.6E-05 Rat1 
keratin complex 1, acidic, gene 14 
(predicted) 56912233 4.4 
Krt18 keratin 18 1388155_at -4.0 3.4E-03 7.9E-03 Rat1 keratin complex 1, acidic, gene 18 60688216 -18.9 
Krt5 keratin 5 1370863_at 2.6 2.8E-03 6.6E-03 Rat1 type II keratin 5 [Mus musculus] 16303309 5.7 
Ldha lactate dehydrogenase A 1367586_at 2.8 7.9E-04 1.4E-03 Rat1 lactate dehydrogenase A 8393706 3.3 
Ldhb lactate dehydrogenase B 1370218_at -2.1 2.6E-03 6.6E-03 Rat1 lactate dehydrogenase B 6981146 -3.5 
Lgals4 lectin, galactoside-binding, soluble, 4 1368269_at 12.7 3.5E-03 7.9E-03 Rat1 
lectin, galactoside-binding, soluble, 4 
(galectin 4) 6981152 4.3 
Nit1 nitrilase 1 1398049_at -1.5 3.5E-03 7.9E-03 Rat1 Nit 1 protein 56268926 -2.4 
S100a4 S100 calcium-binding protein A4 1367846_at 2.6 1.6E-04 2.0E-04 Rat1 S100 A4 (calvasculin) 6981326 5.3 
Serpinh1 
serine (or cysteine) peptidase inhibitor, 
clade H, member 1 1371310_s_at 4.1 3.1E-03 6.6E-03 Rat1 serpinh 1 protein 55824765 4.6 
Vim vimentin 1367574_at 2.6 6.9E-03 1.8E-02 Rat1 vimentin 57480 4.1 
Anxa1  annexin A1  7060990 5.7 4.3E-07 1.6E-06 Rat2 Lipocortin I [Rattus sp.] 235879 3.4 
Anxa2  annexin A2  7337587 1.8 2.6E-05 1.4E-04 Rat2 Calpactin I heavy chain 312253 7.1 
Banf1  barrier to autointegration factor 1  7059728 1.8 4.6E-03 1.9E-02 Rat2 barrier to autointegration factor 1 16758438 4.9 
Car2  carbonic anhydrase II  7206103 3.5 5.0E-04 2.3E-03 Rat2 Ca2 protein (carbonic anhydrase) 41388872 3.4 
Ka11  type I keratin KA11  7082629 11.1 1.9E-09 3.5E-09 Rat2 type I keratin KA11 57012432 4.2 
Krt14  keratin 14  7082623 11.1 1.4E-09 3.4E-09 Rat2 
keratin complex 1, acidic, gene 14 
(predicted) 56912233 4.4 
Krt18  keratin 18  7191382 -4.7 2.3E-06 9.5E-06 Rat2 keratin complex 1, acidic, gene 18 60688216 -18.9 
Ldha  lactate dehydrogenase A  7031732 2.6 7.0E-05 3.1E-04 Rat2 lactate dehydrogenase A 8393706 3.3 
Ldhb  lactate dehydrogenase B  7270937 -2.4 2.1E-07 5.3E-07 Rat2 lactate dehydrogenase B 6981146 -3.5 
Lgals4  lectin, galactoside-binding, soluble, 4  7030215 16.0 1.5E-03 7.4E-03 Rat2 
lectin, galactoside-binding, soluble, 4 
(galectin 4) 6981152 4.3 
Nme2  
non-metastatic cells 2, protein (NM23B) 
expressed in  7081660 1.8 2.0E-03 8.7E-03 Rat2 
RBL-NDP kinase 18kDa subunit 
(p18) 206580 8 
Prosc  
proline synthetase co-transcribed 
homolog (bacterial)  7152637 -1.7 3.5E-06 1.4E-05 Rat2 
similar to Proline synthetase 
associated(predicted) 62662820 -6.1 
Serpina1  
serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 1  7309988 5.8 9.7E-03 4.0E-02 Rat2 serine protease inhibitor alpha 1 51036655 2.5 
Txn1  thioredoxin 1  7286798 1.5 1.8E-03 8.0E-03 Rat2 thioredoxin 16758644 10.4 
Vdac1  voltage-dependent anion channel 1  7067512 1.9 7.2E-03 2.9E-02 Rat2   voltage dependent anion channel 4105605 6.5 
* The DEGs were defined as genes with Q value < 0.01, LFDR < 0.05 and fold change > 1.5 between two groups.  
† Protein expression levels which showed a statistically significant (p<0.05) increase or decrease in tumors as compared with their matched normal bladder.  
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Table 9. Genes exhibited concordant changes at both mRNA expression and protein levels at both rat bladder cancer datasets 
Gene mRNA (Rat_1)  mRNA (Rat_2) 
 
Protein 
 probe_set Normal Tumor Fold   probe_set Normal Tumor Fold 
 
Protein Name Fold 
Anxa1 1367614_at 9.0 12.6 12.3   7060990 1106.1 6285.0 5.7 
 
Lipocortin I [Rattus sp.] 3.4 
Anxa2 1367584_at 10.9 12.3 2.7   7337587 3077.4 5579.3 1.8 
 
Calpactin I heavy chain 7.1 
Krt14 1371895_at 8.2 12.7 22.5   7082623 633.3 7004.7 11.1 
 
keratin complex 1, acidic, gene 14 4.4 
Ldha 1367586_at 9.8 11.3 2.8   7031732 641.3 1646.2 2.6 
 
lactate dehydrogenase A 3.3 
Lgals4 1368269_at 6.8 10.5 12.7   7030215 135.2 2162.5 16.0 
 lectin, galactoside-binding, soluble, 
4  4.3 
Serpinh1 1371310_s_at 7.3 9.3 4.1   7309988 33.4 194.2 5.8 
 
serine protease inhibitor alpha 1 2.5 
Krt18 1388155_at 12.3 10.3 -4.0   7191382 626.6 133.0 -4.7 
 
keratin complex 1, acidic, gene 18 -18.9 
Ldhb 1370218_at 11.4 10.4 -2.1   7270937 2438.2 1010.8 -2.4 
 
lactate dehydrogenase B -3.5 
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Table 10. Molecular pathways identified by gene enrichment analysis in all five datasets 
Gene sets 
Rat_1 Rat_2 Mouse Human_1 Human_2 
Size FDR Size FDR Size FDR Size FDR Size FDR 
The curated gene sets c2          
ADIP_DIFF_CLUSTER4 32 0.012 24 0.000 18 0.006 32 8E-06 32 1E-04 
ADIP_DIFF_CLUSTER5 33 0.039 32 3E-05 16 0.007 35 0.000 35 8E-06 
BASSO_REGULATORY_HUBS 105 0.235 103 0.020 77 0.043 138 0.036 138 0.000 
BENNETT_SLE_UP 20 7E-05 19 0.010 17 0.001 28 0.021 28 0.009 
BRCA_ER_NEG 583 0.002 655 2E-05 494 0.000 867 0.003 867 0.001 
BRCA_PROGNOSIS_NEG 62 0.001 62 0.008 41 0.001 94 4E-05 94 0.000 
BRENTANI_CELL_CYCLE 65 0.182 58 6E-05 49 0.005 80 3E-04 80 0.002 
CANCER_NEOPLASTIC_META_UP 53 0.088 40 0.084 37 0.028 60 0.000 60 0.000 
CANCER_UNDIFFERENTIATED_META_UP 59 0.003 41 3E-05 37 0.000 67 0.000 67 0.000 
CANTHARIDIN_DN 35 0.042 32 0.018 30 0.071 49 4E-04 49 0.000 
CELL_CYCLE 53 0.225 51 7E-05 45 0.002 74 0.000 74 0.000 
CELL_CYCLE_KEGG 58 0.222 58 4E-04 48 0.002 80 0.000 80 8E-06 
CHANG_SERUM_RESPONSE_UP 108 0.241 107 0.013 92 0.013 143 0.002 143 0.000 
CMV_ALL_UP 73 0.239 68 0.057 59 0.154 90 0.167 90 0.006 
CMV_IE86_UP 34 0.072 38 0.003 26 0.088 49 0.000 49 0.000 
CROMER_HYPOPHARYNGEAL_MET_VS_NON_DN 53 0.222 52 4E-04 42 0.003 80 0.020 80 0.000 
CROONQUIST_IL6_STARVE_UP 27 0.011 24 4E-05 20 2E-04 33 0.000 33 8E-06 
DER_IFNA_UP 40 0.010 44 0.074 37 0.019 65 0.042 65 0.001 
DER_IFNB_UP 64 0.047 63 0.184 55 0.063 91 0.139 91 0.001 
DNA_REPLICATION_REACTOME 38 0.012 29 7E-05 24 0.132 44 0.000 44 0.000 
DOX_RESIST_GASTRIC_UP 25 0.043 28 1E-04 15 0.001 43 0.000 43 0.000 
GAY_YY1_DN 212 0.004 193 1E-04 154 0.001 220 7E-06 220 0.051 
GREENBAUM_E2A_UP 29 0.001 27 3E-05 22 2E-04 32 0.000 32 1E-05 
HCC_SURVIVAL_GOOD_VS_POOR_DN 85 0.065 89 0.021 78 0.026 121 4E-04 121 0.000 
HESS_HOXAANMEIS1_DN 61 0.222 46 0.006 41 0.051 55 0.093 55 0.004 
HESS_HOXAANMEIS1_UP 61 0.234 46 0.005 41 0.061 55 0.087 55 0.003 
HG_PROGERIA_DN 19 0.095 20 4E-04 16 0.005 25 3E-04 25 0.012 
HIF1_TARGETS 31 0.030 29 0.001 31 0.003 35 0.021 35 0.005 
HOFFMANN_BIVSBII_BI_TABLE2 226 0.037 150 4E-05 117 0.001 184 7E-06 184 2E-05 
HOFMANN_MDS_CD34_LOW_AND_HIGH_RISK 21 0.204 30 0.018 26 0.004 46 0.042 46 0.017 
HSA03050_PROTEASOME 22 0.236 20 0.007 19 0.135 22 0.002 22 0.000 
HSA04110_CELL_CYCLE 82 0.210 79 3E-04 70 0.001 102 0.000 102 0.000 
HSA04115_P53_SIGNALING_PATHWAY 47 0.217 43 0.002 39 0.002 62 0.020 62 3E-04 
IDX_TSA_UP_CLUSTER3 78 3E-04 66 0.000 42 0.000 83 0.000 83 0.000 
IFN_ALPHA_UP 26 0.100 28 0.214 24 0.027 40 0.239 40 0.020 
IFNA_HCMV_6HRS_UP 33 0.001 32 0.191 25 0.002 53 0.011 53 0.030 
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IFNALPHA_HCC_UP 23 0.012 18 0.157 23 0.005 29 0.047 29 0.005 
IFNALPHA_NL_UP 18 0.018 17 0.218 18 0.012 27 0.013 27 0.002 
INOS_ALL_UP 45 0.177 40 0.036 35 0.159 52 0.005 52 0.000 
KENNY_WNT_UP 34 0.046 34 0.200 29 0.025 46 0.129 46 0.005 
LE_MYELIN_UP 105 0.000 63 0.000 50 0.002 82 3E-05 82 0.000 
LEE_MYC_E2F1_UP 42 0.001 44 0.122 38 3E-04 55 0.015 55 0.051 
LEE_TCELLS2_UP 587 0.082 669 0.005 489 0.011 939 0.037 939 0.004 
LEE_TCELLS3_UP 53 0.010 63 3E-05 34 3E-04 93 0.000 93 1E-05 
LEI_MYB_REGULATED_GENES 239 0.032 234 0.023 200 0.001 317 0.057 317 0.000 
LI_FETAL_VS_WT_KIDNEY_DN 114 0.051 106 0.003 85 0.001 159 0.000 159 0.000 
MYC_ONCOGENIC_SIGNATURE 105 0.217 123 0.096 96 0.062 173 0.021 173 0.005 
MYC_TARGETS 38 0.222 34 0.001 37 0.010 39 0.104 39 0.003 
OLDAGE_DN 38 0.040 33 2E-05 29 0.001 47 0.000 47 0.000 
P21_ANY_DN 26 0.004 27 0.002 22 0.008 32 0.000 32 2E-04 
POD1_KO_UP 256 0.166 282 0.070 210 2E-04 339 0.011 339 0.037 
PRMT5_KD_UP 158 0.082 130 0.013 99 4E-04 166 0.007 166 0.000 
PROTEASOME 17 0.095 15 0.021 16 0.115 17 1E-04 17 2E-05 
PROTEASOME_DEGRADATION 29 0.192 20 0.019 27 0.213 31 0.015 31 9E-06 
RADAEVA_IFNA_UP 33 0.004 32 0.147 37 0.001 50 0.003 50 0.001 
RADIATION_SENSITIVITY 19 0.075 19 0.095 19 0.046 24 0.063 24 0.005 
SANA_IFNG_ENDOTHELIAL_UP 34 0.020 43 0.004 31 0.000 60 0.161 60 0.196 
SCHUMACHER_MYC_UP 43 0.081 35 0.020 31 0.023 50 0.002 50 0.000 
SERUM_FIBROBLAST_CELLCYCLE 83 1E-04 90 0.000 53 0.000 110 0.000 110 0.000 
SERUM_FIBROBLAST_CORE_UP 123 0.132 138 0.010 105 0.049 174 2E-04 174 0.000 
SHEPARD_BMYB_MORPHOLINO_DN 128 0.023 129 0.010 99 0.009 152 4E-05 152 0.020 
SHEPARD_CRASH_AND_BURN_MUT_VS_WT_DN 100 0.120 109 0.115 81 0.056 137 8E-05 137 0.011 
SHEPARD_GENES_COMMON_BW_CB_MO 48 0.004 49 0.072 37 0.064 60 0.000 60 0.008 
SHIPP_FL_VS_DLBCL_DN 29 0.103 27 0.190 28 0.056 34 3E-05 34 0.000 
STEMCELL_EMBRYONIC_UP 1162 0.189 909 0.083 717 0.075 1165 0.050 1165 0.000 
TARTE_PLASMA_BLASTIC 244 0.038 221 5E-05 198 0.001 305 0.000 305 0.000 
UVB_NHEK3_ALL 316 0.084 280 0.001 279 0.004 390 0.237 390 0.000 
UVB_NHEK4_6HRS_UP 21 0.157 19 0.075 19 0.043 27 0.067 27 0.001 
VANTVEER_BREAST_OUTCOME_GOOD_VS_POOR_DN 51 0.001 45 0.006 37 0.002 63 4E-05 63 0.001 
WIELAND_HEPATITIS_B_INDUCED 63 0.000 66 0.018 60 3E-05 106 0.001 106 0.050 
YU_CMYC_UP 43 0.000 28 0.003 20 0.002 27 0.000 27 0.000 
ZELLER_MYC_UP 23 0.047 19 0.014 23 0.057 23 0.030 23 0.001 
ZHAN_MMPC_SIMAL 36 0.239 37 0.011 34 0.008 47 0.071 47 0.011 
ZUCCHI_EPITHELIAL_UP 30 0.095 30 0.072 30 3E-04 41 0.034 41 5E-04 
The curated gene sets c5  
         
APOPTOSIS_GO 307 0.136 322 0.003 269 0.062 380 0.131 380 0.020 
CELL_CYCLE_PHASE 115 0.217 121 0.002 83 0.018 145 0.000 145 0.009 
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CELL_CYCLE_PROCESS 133 0.209 136 0.002 94 0.025 165 0.000 165 0.001 
INTERPHASE 49 0.232 43 0.056 35 0.174 58 0.011 58 0.006 
M_PHASE 74 0.181 83 0.002 53 0.006 95 0.000 95 0.081 
M_PHASE_OF_MITOTIC_CELL_CYCLE 54 0.178 61 9E-05 42 0.001 70 0.000 70 0.007 
MITOSIS 52 0.129 60 1E-04 42 0.001 67 0.000 67 0.009 
MITOTIC_CELL_CYCLE 102 0.141 110 0.002 78 0.019 128 0.000 128 3E-04 
PROGRAMMED_CELL_DEATH 307 0.141 323 0.003 270 0.059 381 0.131 381 0.017 
PROTEOLYSIS 121 0.178 138 0.116 117 0.003 162 0.246 162 0.078 
REGULATION_OF_APOPTOSIS 245 0.161 255 0.004 213 0.050 300 0.082 300 0.029 
REGULATION_OF_DNA_METABOLIC_PROCESS 33 0.134 34 0.001 20 0.217 38 0.130 38 0.115 
REGULATION_OF_MITOSIS 30 0.137 28 4E-04 20 0.016 35 0.000 35 0.049 
REGULATION_OF_PROGRAMMED_CELL_DEATH 245 0.172 256 0.004 214 0.046 301 0.078 301 0.023 
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malignancy [20]. TOP2A has been reported to 
be over-expressed in pancreatic adenocarci-
noma [21], renal medullary carcinomas [22], 
ovarian cancer [23], acute lymphocytic leuke-
mia [24], colorectal cancer [25], gastric 
carcinoma [26] and laryngeal squamous cell 
carcinoma [27]. CCNB2 (Cyclin B2), found 
commonly upregulated, is a member of the 
cyclin family, specifically the B-type cyclins. 
Cyclin B2 also binds to transforming growth 
factor beta RII and thus cyclin B2/cdc2 may 
play a key role in transforming growth factor 
beta-mediated cell cycle control [28]. These 
commonly regulated genes across mouse, rat 
and human may be functionally important 
regulators of bladder tumorigenesis.  
 
To integrate the expression changes observed 
in multiple datasets we utilized pathway analy-
sis algorithms to identify functional classifica-
tions that were altered in bladder tumors com-
pared to normal bladder epithelium of mouse, 
rat and human. Biological processes and mo-
lecular functions that were enriched in tumors 
included apoptosis, cell cycle, and DNA replica-
tion. In particular, TOP2A was consistently acti-
vated in the biological classification of regula-
tion of programmed cell death. Several genes 
including CCNB2, KIF20A and TOP2A have pre-
viously been reported to be up-regulated in 
bladder carcinogenesis [29]. CCNB2 was also 
found to be up-regulated in the cell cycle. Addi-
tional pathways enriched in bladder tumors in-
cluded those for interphase and proteolysis. Our 
data suggest that human bladder cancer and 
carcinogen-induced rodent models may show 
more common similarity at global cellular path-
way levels than at the single-gene levels previ-
ously described.  
 
The proportion of dysregulated orthologous 
genes overlapped in two species is low which 
Figure 2. Cell cycle genes consistently altered across species during bladder carcinogenesis. Red and blue indicates 
overexpressed and underexpressed genes in tumor samples, respectively. 1, dataset Rat_1; 2, Rat_2; 3, Mouse; 4, 
Human_1; and 5, Human_2.  
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may be partly explained by the histological dif-
ference in bladder cancer among mouse, rat 
and human. Histopathology of B6D2F1 mouse 
bladder cancers have previously shown that 
these urinary bladder carcinomas had either 
transitional cell differentiation alone or in com-
bination with either squamous or glandular dif-
ferentiation or both squamous and glandular 
differentiation [2]. These patterns were also 
observed in highly invasive variants of human 
transitional cell bladder carcinoma [30]. Immu-
nohistochemical staining of intermediate fila-
ment types showed that OH-BBN-induced rat 
bladder tumors had marked quantitative and 
qualitative differences from the most common, 
purely transitional, human bladder carcinomas 
[31]. Smaller lesions were similar to human 
urothelial dysplasia both histologically and im-
munohistochemically. Progression of the lesions 
demonstrated large exophytic papillomas with 
extensive endophytic epithelial growth into 
abundant stroma and these lesions showed 
increasing predominance of squamous over 
transitional elements. Immunohistochemical 
findings confirmed these results and also dem-
onstrated that morphologically indistinct cells, 
Figure 3. Network analyses of apoptosis, programmed cell death and cell death. Multiple genes in this network are 
dysregulated in bladder tumors. Red and blue indicates overexpressed and underexpressed genes in tumor samples, 
respectively. 
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even in early lesions, express heavier cy-
tokeratins characteristic of keratinizing 
squamous epithelium [30, 31]. The proportion 
of invasive transitional cell carcinomas in hu-
man bladder cancer biopsies from Sanchez-
Carbayo et al. (81/108) is much higher than 
that from Dyrskjøt et al. (13/41) [10] and this 
may explain why there was more gene expres-
sion overlap between the rodent models and 
human bladder cancer from Sanchez-Carbayo et 
al. than those from Dyrskjøt et al. (4.1-4.8% vs. 
2.6-4.0%). These data also suggest that histol-
ogy information should be taken into account 
when analyzing animal models of bladder can-
cer.  
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